市场调查报告书
商品编码
1587080
细菌检测市场:按细菌类型、按测试方法、按成分、按应用、按地区、机会、预测,2017-2031Bacteriological Testing Market Assessment, By Bacteria Type, By Testing Method, By Component, By Application, By Region, Opportunities and Forecast, 2017-2031F |
全球细菌检测市场规模预计将从2023年的155.3亿美元成长到2031年的289.8亿美元,2024-2031年预测期间复合年增长率为8.11%。由于投资者和市场参与者的意识不断提高以及兴趣不断增长,预计细菌学检测的市场需求将在预测年内呈指数级增长。
细菌学检测对于检测和分析食品样本、水样本、药物样本和其他临床标本中的细菌是必要的,以确保公众的健康和安全。这个市场是由对细菌感染和食物中毒的健康担忧以及政府和卫生机构的严格监管所推动的。市场分为培养基、试剂、试剂盒和设备等产品类型,这些产品由于易于使用而越来越受欢迎。应用包括临床诊断、环境测试、食品和饮料安全以及製药。
细菌感染是由有害细菌或毒素(更具体地称为毒素)生长引起的任何病症或疾病。这些由有害细菌引起的感染可以透过环境、接触受感染的个人或动物或受污染的物体(例如食物、水和表面)传播。例如,2024 年 6 月,One Health Trust 报告称,细菌感染每年导致估计 770 万人死亡,其中 495 万人与对抗生素产生抗药性的细菌有关。2024 年 1 月 19 日,ELITechGroup 推出了 ELiTe MGB First Kit,这是一种针对胃肠道感染的细菌病原体组合,以扩大其体外诊断产品组合。
本报告考察了全球细菌学检测市场,并提供了市场概况,包括按细菌类型、检测方法、成分、应用、区域和参与市场的公司概况划分的趋势。
Global bacteriological testing market is projected to witness a CAGR of 8.11% during the forecast period 2024-2031, growing from USD 15.53 billion in 2023 to USD 28.98 billion in 2031. The market demand for bacteriological testing is anticipated to thrive drastically in the forecast years due to rising awareness and the growing interest of investors and market players.
Bacteriological testing is necessary for detecting and analyzing bacteria in food samples, water samples, pharmaceutical samples, and other clinical specimens, thereby ensuring public health and safety. The driving forces for this market are health concerns over bacterial infections and foodborne diseases and strict regulatory compliance from governments and health organizations. The market is segmented into different product types, such as culture media, reagents, kits, and equipment, gaining popularity due to their ease of use. Applications exist in clinical diagnostics, environmental testing, food and beverage safety, and pharmaceutical applications. Bacterial infection refers to any condition or disease coming from the growth of harmful bacteria or poisons, more specifically called toxins. Those infections caused by harmful bacteria can be acquired through contact with the environment, an infected individual or animal, or through something contaminated such as food, water, or surfaces. For instance, in June 2024, One Health Trust reported that Bacterial infections cause an estimated 7.7 million deaths annually, 4.95 million of which are associated with bacteria resistant to antibiotics. On 19 January 2024, ELITechGroup launched their ELiTe MGB first kit of the bacterial pathogens panel targeting gastrointestinal infection, to expand its in vitro diagnostic portfolio.
Increased Prevalence of Bacterial Infections to Drive Market Growth
The increased prevalence of bacterial infections is a significant factor leading to the growth of the market for bacteriological testing. The need for diagnostic testing is becoming more demanding. The surge in gastrointestinal infections has been a result of urbanization and changing lifestyles that resulted in the development of infectious diseases, such as tuberculosis and MRSA infections. This growing burden of bacterial infections requires rapid and accurate diagnosis to treat and control outbreaks quickly. Thus, with healthcare providers and policymakers becoming increasingly aware of these emergencies, the necessity for bacteriological testing is increasing so as to bring attention to diagnostics in public health management. Another reason this market faces an increased demand for bacteriological testing is due to frequent outbursts of foodborne illnesses caused by bacteria such as salmonella, E. coli, and legionella. For instance, in December 2023, HiMedia-HiGenoMB joined a collaboration with NG Biotech, a France-based company, after the Central Drugs Standard Control Organization (CDSCO) approved for importing an NG-Test CARBA 5 kit from NG Biotech. The kit is a rapid test for the qualitative detection and differentiation of five common carbapenemase enzymes (KPC (K), OXA-48-like (O), IMP (I), VIM (V), NDM (N)) in bacterial colonies.
Increasing Health and Safety Awareness and Advancement in Technology to Drive Market Growth
The bacteriological testing market is driven by increasing health and safety awareness. Increasing consciousness about hygiene and contamination risks among consumers and organizations creates a high demand for micro-organism security of food, water, and healthcare. High concern generated by this increased awareness leads to increased demand for reliable bacteriological testing to ensure product standards and protect public health. Educational campaigns and changes in regulations bring better emphasis to regular testing, making businesses and laboratories operate on more stringent testing practices. Advancements in bacteriological testing, have transformed the market with tremendous improvements in diagnostic accuracy, speed, and efficiency. For instance, this technology development in polymerase chain reaction (PCR) and next-generation sequencing mechanisms could enable quicker identification of bacterial pathogens in simple and complex samples with the possibility of accelerated decision-making in clinical and environmental setups. As technology continues to advance, the bacteriological testing market is ripe for future growth. For instance on 29 January 2024, Charles River Laboratories International, Inc. launched the First Rapid Animal-Free Bacterial Endotoxin Test, the Endosafe Trillium recombinant cascade reagent (rCR), expanding its robust bacterial endotoxin testing (BET) portfolio.
Food and Beverage Testing Segment to Dominate the Bacteriological Testing Market Share
The food and beverage testing segment is expected to dominate the share of the global bacteriological testing market. Rising consumer awareness about food safety and quality is driving the increasing demand in this sector. With the increasing incidence of foodborne illnesses and increased regulatory requirements, food manufacturers are adopting microbiological testing as a significant measure to render their products free from harmful pathogens. This segment encompasses a spectrum of testing methodologies, ranging from elementary observations and sampling to highly sophisticated molecular methods that yield quick and reliable responses. Additionally, increased openness about food sources and production chains has become the norm, putting more pressure on companies to be more stringent in testing procedures, and thus, the demand for bacteriological test products has soared due to this reason. This segment is likely to grow and become a leader in the market.
According to the National Centre for Disease Control Data, in March 2024, food poisoning and diarrhea are increasingly more prevalent. Food Safety and Standards Authority of India (FSSAI) is working to establish a network of 34 microbiology labs across the country, all of which would be equipped to test food products for ten pathogens, including E. coli, Salmonella, and Listeria.
North America to Dominate Bacteriological Testing Market Share
North America is anticipated to dominate the share of the bacteriological testing market due to several factors, such as the high prevalence of bacterial infections and advancements in technology. For instance, in November 2023, according to the Centers for Disease Control and Prevention (CDC), at least 2.8 million people in the United States get antibiotic-resistant infections each year, and more than 35,000 die from these infections. The presence of key players in the biotechnology and diagnostics segments, along with significant investments in R&D have propelled market growth. As consumers increasingly focus their attention on health and safety, the trend for accurate and rapid testing solutions is bound to sustain the leadership North America maintains in the global bacteriological testing landscape. For instance, in June 2024, QIAGEN announced the launch of the QIAstat-Dx Gastrointestinal Panel 2 in the United States. The launch comes after recent clearance by the FDA, after which the syndromic test was granted approval for its clinical use, an important advancement in improving the efficiency and accuracy of gastrointestinal (GI) infection diagnosis.
Future Market Scenario (2024-2031F)
The future market scenario of the bacteriological testing market is poised for significant growth, driven by increased awareness and prevalence of infectious diseases and advancement in testing technology. Innovations such as rapid testing methods, automation, and artificial intelligence have improved bacteriological assays' accuracy and efficiency, making them accessible to many sectors, including healthcare, food safety, and environmental monitoring. Also, the growing threat of antimicrobial resistance and the development of personalized medicine create greater demand for advanced testing capabilities. Increasingly stringent regulatory guidelines and shifts in global health threats will ensure considerable growth in the demand for bacteriological testing. The work will be driven by emergent markets. It is a vision of new methodologies for testing and expanding markets that can capture and benefit from public health around the world. For instance, in February 2024, Charles River Laboratories., a microbial solutions company based in the United States, expanded its bacterial endotoxin testing (BET) portfolio with a new animal-free solution, building on its Trillium rCR product. The pre-loaded rCR cartridges simplify testing by removing the need for multiple reagent preparations, offering faster, accurate results while reducing technician error.
Key Players Landscape and Outlook
The bacteriological testing market is highly competitive, with numerous key players driving growth through strategic business agreements, collaborations, and regulatory product approvals. In recent years, there has been a significant increase in activities, reinforcing the market's dynamic nature. Additionally, smaller companies contribute to the market landscape by engaging in partnerships with established players. This collaborative approach enables the industry to meet the evolving needs of various end-users efficiently and maintain a robust market presence.
For instance, in September 2024, LuminUltra Technologies Ltd. expanded its molecular testing portfolio by acquiring the Legionella testing business assets of Genomadix Inc. This strategic acquisition enhances LuminUltra Technologies Ltd.'s capabilities in rapid identification and quantification of Legionella microbes across residential, commercial, and industrial water systems, reinforcing its position in water quality monitoring solutions.
In June 2022, STEMart Inc. launched microbiology & sterility testing services for medical devices, offering expertise to help manufacturers meet regulatory standards and reduce compliance risks through a full-service and end-to-end solution.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.